TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
暂无分享,去创建一个
A. Børresen-Dale | M. Olivier | P. Hainaut | A. Petitjean | M. Achatz | M. Achatz | P Hainaut | M Olivier | A Petitjean | M I W Achatz | A L Borresen-Dale
[1] M. Hollstein,et al. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumours , 2009, International journal of cancer.
[2] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[3] A. Fersht,et al. Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations* , 2005, Journal of Biological Chemistry.
[4] R. Eeles. Germline mutations in the TP53 gene. , 1995, Cancer surveys.
[5] M. Hollstein,et al. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.
[6] J. Wands,et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.
[7] R. Ribeiro,et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.
[8] J. Varley,et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.
[9] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[10] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[11] M. Hollstein,et al. p53 Designer Genes for the Modern Mouse , 2004, Cell cycle.
[12] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Spitz,et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.
[14] F. Pontén,et al. Molecular pathology in basal cell cancer with p53 as a genetic marker , 1997, Oncogene.
[15] Peter A. Jones,et al. Methylation, mutation and cancer , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.
[16] S. Friend,et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast , 1993, Nature genetics.
[17] S. Bull,et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[19] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[20] R. Kreienberg,et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations , 1999, British Journal of Cancer.
[21] M. Hollstein,et al. Ser46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence , 2006, Cell cycle.
[22] S. Wingren,et al. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients , 2006, Pharmacogenetics and genomics.
[23] Yuntao Xie,et al. p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer , 2005, Clinical Cancer Research.
[24] C. Harris,et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer , 2007, Oncogene.
[25] S. Sommer,et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Andrew D. Yates,et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.
[27] W. Mcdougal. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.
[28] A. Levine,et al. Single-nucleotide polymorphisms in the p53 pathway. , 2005, Cold Spring Harbor symposia on quantitative biology.
[29] T. Rebbeck,et al. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. , 1998, Anticancer research.
[30] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[31] P. Lønning,et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[32] T. Crook,et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.
[33] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[34] S. Friend,et al. A functional screen for germ line p53 mutations based on transcriptional activation. , 1992, Cancer research.
[35] T. Frebourg,et al. Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 gene , 2003, Oncogene.
[36] Francesca Storici,et al. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.
[37] Hongjuan Zhao,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.
[38] E. Guinó,et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA , 2004, Oncogene.
[39] K. Wiman,et al. Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs* , 2005, Journal of Biological Chemistry.
[40] A. Børresen-Dale,et al. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival , 2004, British Journal of Cancer.
[41] G. Giglia-Mari,et al. TP53 mutations in human skin cancers , 2003, Human mutation.
[42] C. Marsit,et al. TP53 mutation, allelism and survival in non-small cell lung cancer. , 2005, Carcinogenesis.
[43] H. Johnsen,et al. p53 polymorphism and risk of cervical cancer , 1998, Nature.
[44] R. Birgander,et al. Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.
[45] D. Pim,et al. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.
[46] C. Harris,et al. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. , 2004, IARC scientific publications.
[47] C. Bonaïti‐pellié,et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.
[48] L. Bracco,et al. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments , 1999, Oncogene.
[49] M. Vidal,et al. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[50] T. Lindahl. Instability and decay of the primary structure of DNA , 1993, Nature.
[51] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[52] Andrew Shenton,et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.
[53] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[54] Yusuke Nakamura,et al. p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.
[55] T. Soussi,et al. Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. , 1994, The EMBO journal.
[56] M. Hollstein,et al. Mouse models for generating P53 gene mutation spectra. , 2002, Toxicology letters.
[57] A. Fersht,et al. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.
[58] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[59] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[60] A. Fersht,et al. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.
[61] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[62] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[63] A. Børresen-Dale,et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma , 2004, Human mutation.
[64] M. Hollstein,et al. MEF immortalization to investigate the ins and outs of mutagenesis. , 2006, Carcinogenesis.
[65] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[66] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[67] M. Hollstein,et al. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. , 2007, Oncogene.
[68] T. Eisen,et al. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. , 2003, Mutagenesis.
[69] M. Olivier,et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. , 2007, Cancer letters.
[70] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[71] Irene M. Leigh,et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.
[72] M. Hollstein,et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool , 2001, Oncogene.
[73] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[74] R. Iggo,et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. , 2001, Carcinogenesis.
[75] J. Delgado,et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. , 2006, Leukemia research.
[76] H. Stunnenberg,et al. Characterization of genome-wide p53-binding sites upon stress response , 2008, Nucleic acids research.
[77] R. Beart,et al. Mechanisms for the involvement of DNA methylation in colon carcinogenesis. , 1996, Cancer research.
[78] B. Iacopetta,et al. Clonal Analysis of Colorectal Tumors Using K-ras and p53 Gene Mutations as Markers , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[79] D. Evans,et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.
[80] P. Hainaut,et al. On the origin of G --> T transversions in lung cancer. , 2003, Mutation research.
[81] R. Eeles,et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.
[82] Jacqueline Lehmann,et al. TP53 Status and Response to Chemotherapy in Breast Cancer , 2008, Pathobiology.
[83] Frank M Boeckler,et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.
[84] T. Kirchhoff,et al. A double germline mutations in the APC and p53 genes. , 2000, Neoplasma.
[85] Hans Clevers,et al. Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.
[86] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[87] M. Tang,et al. Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.
[88] L. R. Dearth,et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. , 2007, Carcinogenesis.
[89] C. Crum,et al. Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma , 2008, Clinical Cancer Research.
[90] B. Jelaković,et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.
[91] P. Hainaut,et al. Molecular precursor lesions in oesophageal cancer. , 1998, Cancer surveys.
[92] R. Catarino,et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. , 2006, Biochemical and biophysical research communications.
[93] B. Vogelstein,et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[94] N. Muñoz,et al. TP53 polymorphism, HPV infection, and risk of cervical cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[95] W. Blattner,et al. A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.
[96] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[97] J. Garber,et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. , 2006, Gastroenterology.
[98] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[99] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[100] K. Sabapathy,et al. Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs , 2005, Clinical Cancer Research.
[101] A. Metspalu,et al. Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. , 2005, Clinical chemistry.
[102] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[103] Robert W Platt,et al. p53 Codon 72 Polymorphism and Cervical Neoplasia , 2004, Cancer Epidemiology Biomarkers & Prevention.
[104] R. A. Metcalf,et al. Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.
[105] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[106] K. Sabapathy,et al. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism , 2006, Oncogene.
[107] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[108] E. Appella,et al. Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. , 2006, Cancer research.
[109] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[110] C. Marsit,et al. TP 53 mutation , allelism and survival in non-small cell lung cancer , 2005 .
[111] Miranda Thomas,et al. Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.
[112] C. Franceschi,et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[113] N. Tretyakova,et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.
[114] G. D’Orazi,et al. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway , 2007, Cell Death and Differentiation.
[115] Jotun Hein,et al. A nucleotide substitution model with nearest-neighbour interactions , 2004, ISMB/ECCB.
[116] Graham M Lord,et al. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer , 2007 .
[117] R. Schneider-Stock,et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. , 2004, The American journal of pathology.